A Rare Mesothelioma Under The Cloak Of Heart Failure And Constrictive Pericarditis

Muhammad Osama,Venkata Satish Pendela,Vishal Parikh

DOI: https://doi.org/10.1016/j.cardfail.2023.10.208

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Primary pericardial mesothelioma (PPM) is a rare and highly aggressive malignancy that arises from the serosal lining of the pericardium with an incidence of 0.0022%. It is a diagnostically challenging neoplasm due to its non-specific presentation. There is a lack of guideline-directed management due to the scarcity of literature. We present a case of PPM treated with Nivolumab plus ipilimumab. Case Presentation A 59-year-old woman presented to the hospital with dyspnea and dizziness on minimal exertion worsening over a few weeks. She had diminished heart sounds on the exam. ECG showed T wave inversions in inferolateral leads (Fig 1A). A transthoracic echocardiogram revealed a moderate-sized pericardial effusion without any evidence of tamponade (Fig 1B). A pericardiocentesis was performed with the removal of 1.5 liters of straw-colored fluid. Cytology revealed atypical mesothelial cells. Subsequently, she underwent pericardial window due to recurrent effusion. She had recurrent admissions for heart failure exacerbation and volume overload symptoms. A TTE was repeated which showed lateral E’ < medial E’ prime concerning for constrictive physiology (Figs 1C & 1D). A right heart catheterization revealed a rapid steep Y descent (Fig 1E). Cardiac MRI showed significantly elongated atria with small ventricles, along with complex lobulated pericardial effusion and thickening, confirming the diagnosis of effusive constrictive pericarditis (Fig 1F). During the course, her symptoms worsened, and she underwent pericardiectomy. The mucinous fluid and the fibrin material from the surgery were positive for epitheloid-type pericardial malignant mesothelioma. She was started on immune therapy with Ipilimumab and Nivolumab. Her progress is being monitored. Conclusion PPM is an aggressive malignancy with high mortality, unclear etiology, and non-specific presentation without an established treatment strategy. The patient's presentation ranges from acute tamponade to heart failure exacerbation and subacute constrictive pericarditis. Our patient had multiple admissions with heart failure exacerbations. Our case also demonstrates significant challenges in the diagnosis and management of this malignancy. The median survival is 6 months. Treatment offered for PPM includes surgery, radiation, and chemotherapy. Therapy with platinum-based agents has shown survival benefits. U.S. FDA has approved Ipilimumab and Nivolumab for their superiority over platinum-based agents in malignant pleural mesothelioma (MPM), however, this strategy has not been used in PPM before. Early multi-disciplinary involvement with heart failure specialists, surgeons, and oncologists can aid in a better prognosis.

cardiac & cardiovascular systems